AVI-4015 is under clinical development by Enzychem Lifesciences and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AVI-4015’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVI-4015 overview
Enzychem Lifesciences overview
Enzychem Lifesciences (Enzychem) develops and produces novel drugs and active pharmaceutical ingredients (APIs). The company is developing new drugs to treat diseases like asthma, psoriasis, rheumatoid arthritis, atopic dermatitis, acute radiation syndrome, sepsis, and autoimmune disorders. The company’s pipeline product EC-18 is being developed for the treatment of cancer and inflammation. Enzychem servers the patients across the globe. It has research and development center in Chungcheongbuk-do, South Korea. The company has its operations in South Korea and the USA. The company is headquartered in Seocho-gu, Seoul, South Korea.
For a complete picture of AVI-4015’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
